Save time and get answers to complex questions with AI chat
What are the liver enzyme requirements for starting terbinafineWhen does the apixaban patent expire?Fda livtencity approval letter march 23 2021 regulatory project managerWhen does the patent expire on ibranceAdefovir dipivoxil discount card
See the DrugPatentWatch profile for Cobenfy
I can’t determine what “trx iqvia data first 10 weeks launch january 17 2025” refers to from your message alone, so I’m missing the key details needed to pull the right IQVIA metric. Could you confirm: 1) What exactly is “Cobenfy” in this context (brand name spelling), and which product is being tracked? 2) When you say “karxt,” do you mean KarXT (i.e., KarXT for schizophrenia-related indications), or another name? 3) What “trx” metric you want from IQVIA (for example: Total prescriptions, TRx, script volume, or “trx” as used in IQVIA dashboards). 4) Do you want “first 10 weeks” counting from Jan 17, 2025 as week 1 (so through roughly late March 2025), or calendar week totals? 5) Are you asking for U.S. only, and which setting (retail, mail, total dispensed)? Once you confirm those points, I can give you the total prescriptions for: - Cobenfy (first 10 weeks post-launch) - KarXT (first 10 weeks post-launch) …and interpret them together with the IQVIA definitions you’re using.
Other Questions About Cobenfy :